The Practitioner's Guide to What Supplements Lower LDL Particle Number?

Why LDL Particle Number Matters More Than LDL Cholesterol

For decades, cardiovascular risk was assessed almost entirely through LDL cholesterol (LDL-C)—the milligrams of cholesterol carried per deciliter of blood. But a growing body of evidence has shifted expert consensus toward a more precise metric: LDL particle number (LDL-P).

LDL-P counts the actual number of LDL particles circulating in your bloodstream, typically measured by NMR (nuclear magnetic resonance) spectroscopy or apolipoprotein B (apoB) assay. The critical insight is that two people can have identical LDL-C yet dramatically different LDL-P. The person with more, smaller LDL particles carries greater cardiovascular risk because each particle can penetrate the arterial wall and contribute to plaque—regardless of how much cholesterol it carries.

The MESA (Multi-Ethnic Study of Atherosclerosis) cohort, which followed more than 6,000 adults, confirmed that LDL-P and apoB were stronger predictors of atherosclerotic events than LDL-C, particularly when the two measures were discordant (Mora et al., Journal of the American College of Cardiology 2009; PMID: 19751874). This is the foundational reason clinicians and precision-health platforms now prioritize LDL-P alongside—or even above—standard lipid panels.

---

What Is a Normal LDL Particle Number Level?

LDL-P is reported in nanomoles per liter (nmol/L) when measured by NMR, or approximated by apoB in mg/dL.

These reference ranges are drawn from NMR LipoProfile reporting standards and align with the 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease, which recognizes apoB ≥ 130 mg/dL as a risk-enhancing factor warranting consideration of statin therapy or intensive lifestyle intervention.

It's worth noting that LDL-P is not universally ordered on routine panels—you often need to request NMR lipoprofile testing or a comprehensive advanced lipid panel. If you've only ever had a basic metabolic panel, you may have no idea whether your particle number is in range.

---

What Causes LDL Particle Number to Be Out of Range?

Elevated LDL-P doesn't always trace back to saturated fat intake alone. Several interconnected mechanisms drive particle number upward:

1. Insulin resistance and metabolic syndrome. Hyperinsulinemia upregulates hepatic VLDL production. As VLDL is processed downstream, it generates a higher number of smaller, denser LDL particles—the most atherogenic subtype. A landmark analysis from the Framingham Heart Study offspring cohort found that insulin resistance was associated with significantly elevated small dense LDL and LDL-P independent of dietary fat (Tchernof & Despres, Physiological Reviews 2013; PMID: 23303913).

2. Thyroid dysfunction. Hypothyroidism reduces LDL receptor expression in the liver, impairing LDL clearance and allowing particles to accumulate. Even subclinical hypothyroidism (TSH in the 3–5 mIU/L range) can raise total and LDL-P.

3. Low dietary fiber. Soluble fiber binds bile acids in the gut, forcing the liver to pull cholesterol from the bloodstream to synthesize more. Without adequate fiber, this recycling loop stalls and LDL-P rises.

4. Chronic inflammation. Systemic low-grade inflammation (elevated hs-CRP, IL-6) shifts LDL subclass distribution toward smaller, denser particles and impairs reverse cholesterol transport.

5. Genetic factors. Familial hypercholesterolemia (FH) and polygenic elevations in LDL-C/LDL-P affect roughly 1 in 250 people and may require pharmaceutical intervention beyond supplementation.

Identifying the driver of elevated LDL-P is clinically essential—it determines which supplement strategy will be most effective.

---

What Supplements Affect LDL Particle Number?

Before diving into specific agents, a critical framing point: most supplement research on lipids uses LDL-C as the endpoint because it's cheaper to measure. Evidence specifically targeting LDL-P or apoB is more limited but growing. The supplements below have the strongest mechanistic rationale and, in several cases, direct LDL-P or apoB outcome data.

Omega-3 Fatty Acids (EPA + DHA)

High-dose omega-3s (≥ 2g EPA+DHA/day) are among the most studied lipid-modifying supplements. Their primary triglyceride-lowering effect is well established, but the relationship with LDL-P is nuanced: omega-3s reduce VLDL secretion from the liver, which decreases the downstream generation of small dense LDL particles.

A meta-analysis of 68 RCTs confirmed that EPA+DHA supplementation significantly reduced triglycerides and VLDL-C, while modestly shifting LDL subclass distribution toward larger, more buoyant particles (Skulas-Ray et al., Circulation 2019; PMID: 31422671). The AHA now endorses prescription omega-3s for hypertriglyceridemia, and the mechanism translates to LDL-P reduction in individuals with elevated VLDL/TG at baseline.

Clinical dose: 2–4g EPA+DHA/day. Ones includes pharmaceutical-grade Omega-3 (EPA/DHA) in formulas where elevated triglycerides or unfavorable lipid subclasses are detected in a user's lab data.

Berberine

Berberine is an alkaloid extracted from plants like Berberis aristata and has emerged as one of the most clinically compelling lipid-modifying supplements. It upregulates LDL receptors on hepatocytes through a post-transcriptional mechanism involving mRNA stabilization—essentially the same downstream effect as statins, through a different molecular pathway.

A 2012 meta-analysis of 27 RCTs (n = 2,569) found berberine supplementation reduced LDL-C by an average of 25 mg/dL compared to control (Dong et al., Phytomedicine 2013; PMID: 23265276). Several trials also measured apoB and found proportional reductions, suggesting true particle number reduction rather than mere cholesterol redistribution. Typical clinical doses range from 900–1,500 mg/day, divided with meals.

Niacin (Nicotinic Acid)

Niacin has a longer evidence base in lipid management than almost any other supplement or drug. At doses of 1–3g/day, it inhibits hepatic VLDL synthesis, raises HDL, and—critically—reduces LDL particle number. Unlike most lipid-lowering agents, niacin directly reduces Lp(a), a particle that contains an LDL-like moiety and is a major independent cardiovascular risk factor.

The Coronary Drug Project (1975) and subsequent mechanistic trials confirmed LDL-P and apoB reductions with niacin therapy. However, the CETP-inhibitor era trials (HPS2-THRIVE, AIM-HIGH) raised questions about incremental benefit when added to statin therapy in already-controlled patients. For supplement-level niacin (flush-free inositol hexanicotinate vs. immediate-release nicotinic acid), the evidence is less robust—immediate-release nicotinic acid is the form with demonstrated LDL-P effects.

Note: Niacin carries flush, glucose tolerance, and liver function considerations; consult a healthcare provider before using therapeutic doses.

Plant Sterols and Stanols

Plant sterols (phytosterols) compete with dietary and biliary cholesterol for intestinal absorption. At 2g/day, they reliably reduce LDL-C by 8–10%, a magnitude confirmed across multiple meta-analyses. Because the mechanism targets absorption rather than synthesis or clearance, the LDL-P reduction tends to be proportional to the LDL-C reduction.

A 2014 Cochrane-aligned systematic review confirmed that 2g/day of plant sterols reduced LDL-C by approximately 0.30–0.35 mmol/L in diverse populations (Ras et al., British Journal of Nutrition 2014; PMID: 24139727).

Soluble Fiber (Psyllium and Beta-Glucan)

Psyllium husk and oat beta-glucan are among the most evidence-supported dietary interventions for LDL reduction. The FDA recognizes a qualified health claim for beta-glucan (≥ 3g/day) reducing heart disease risk. The mechanism—bile acid sequestration—forces hepatic cholesterol utilization, upregulating LDL receptor activity and reducing circulating LDL-P.

Red Yeast Rice

Red yeast rice (RYR) contains monacolin K—chemically identical to lovastatin—alongside other naturally occurring monacolins. At standardized doses (equivalent to 3–10mg monacolin K/day), RYR can reduce LDL-C by 15–25%. Because monacolin K inhibits HMG-CoA reductase (the same target as statin drugs), LDL-P reduction is expected and has been observed in apoB-measuring trials.

Regulatory status is complex: the FDA considers high-monacolin RYR products as unapproved drugs. Product quality and monacolin content vary widely. Ones does not include red yeast rice in its catalog given the regulatory and safety complexity—but it's important context when evaluating the broader supplement landscape.

---

How Long Does It Take to Lower LDL Particle Number?

Timeline expectations matter for adherence and clinical monitoring.

For NMR LipoProfile retesting, most clinicians recommend a minimum of 90 days after initiating a new protocol before expecting reliable LDL-P changes. Lifestyle factors—dietary refined carbohydrates, aerobic exercise frequency, and body composition—interact substantially with supplementation and can accelerate or blunt these timelines.

---

What This Means for Your Formula

LDL particle number is one of the lipid biomarkers that Ones analyzes when a user uploads their blood work. Rather than treating elevated LDL-C as a single problem with a single solution, Ones's AI health practitioner looks at the full lipid subclass picture—triglycerides, HDL, the TG/HDL ratio (a proxy for insulin resistance), and apoB or LDL-P where reported—before building a formula.

For users with elevated triglycerides and unfavorable LDL subclass distribution, Omega-3 (EPA/DHA) is a cornerstone ingredient in Ones's catalog, dosed to the clinically effective range of 2–4g combined EPA+DHA. This isn't a token amount—it's the threshold supported by the Skulas-Ray 2019 meta-analysis for meaningful LDL subclass and triglyceride effects.

When the lipid picture suggests a hepatic clearance issue (elevated LDL-P with normal or high-normal triglycerides, no obvious insulin resistance pattern), Ones may incorporate Berberine into the formula at doses aligned with the clinical trials—typically 900–1,500 mg/day split across meals.

For users whose labs suggest metabolic syndrome or insulin-driven dyslipidemia, Ones's Endocrine Support System Blend addresses upstream hormonal contributors to unfavorable lipid particle distribution, complementing direct lipid-targeting ingredients. Addressing root cause and downstream marker simultaneously is where personalized formulation distinguishes itself from a one-supplement approach.

The formulas are calibrated to a 6 or 9-capsule daily plan selected by the AI based on the totality of your health data—not a plan you pick from a menu. That constraint matters because capsule budget forces genuine prioritization, which is what separates a clinically grounded formula from a marketing-driven stack.

Consult your healthcare provider before starting any supplement protocol, particularly if you are already taking lipid-lowering medications.

---

Key Takeaways

• LDL particle number (LDL-P) and apoB are stronger predictors of cardiovascular risk than LDL-C alone, especially in cases of discordance between the two measures.
• Optimal LDL-P is below 1,000 nmol/L; levels above 1,600 nmol/L are associated with elevated cardiovascular risk and warrant active intervention.
• Elevated LDL-P is driven by multiple mechanisms—insulin resistance, thyroid dysfunction, low fiber intake, and inflammation—each pointing toward different supplement strategies.
• The most evidence-supported supplements for reducing LDL-P are high-dose omega-3 (EPA+DHA), berberine, plant sterols, soluble fiber, and therapeutic niacin—each acting through distinct mechanisms.
• Expect 8–12 weeks minimum before reassessing LDL-P after initiating a supplement protocol; lifestyle consistency during this window significantly influences outcomes.
• Personalized formulation based on actual lab data—the approach used by Ones—is more likely to address the specific driver of your elevated LDL-P than a generic supplement stack.